ACM
ABBV icon

Axel Capital Management’s AbbVie ABBV Stock Holding History

Axel Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-59,000
Closed -$9.56M – 3
2022
Q1 		$9.56M Buy
59,000
+42,000
+247% +$6.1M 12.13% 2
2021
Q4 		$2.3M Buy
+17,000
New +$2.01M 2.26% 12
2021
Q1 		– Sell
-2,598
Closed -$278K – 38
2020
Q4 		$278K Hold
2,598
– – 0.09% 38
2020
Q3 		$228K Hold
2,598
– – 0.1% 38
2020
Q2 		$255K Buy
+2,598
New +$229K 0.19% 31

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axel Capital Management's ABBV Position: Q2 2022 in Review

Axel Capital Management sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 59,000 shares — an estimated $9.56M sold.

Axel Capital Management first reported a position in ABBV in Q2 2020 and held it in 5 quarters. The position peaked at $9.56M in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Axel Capital Management reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
  • Axel Capital Management sold 59,000 AbbVie shares in Q2 2022, an estimated $9.56M.
  • Axel Capital Management first reported a position in AbbVie in Q2 2020 and held it in 5 quarters.
  • Axel Capital Management's AbbVie position peaked at $9.56M in Q1 2022.
  • 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Axel Capital Management's 13F filing for Q2 2022, filed 3 Aug 2022.